1. Effects of Rowachol on prevention of postcholecystectomy pain after laparoscopic cholecystectomy: prospective multicenter randomized controlled trial.
- Author
-
Han IW, Kwon OC, Oh MG, Choi YS, and Lee SE
- Subjects
- Abdominal Pain diagnosis, Abdominal Pain etiology, Administration, Oral, Adult, Aged, Analgesics adverse effects, Chi-Square Distribution, Drug Administration Schedule, Drug Combinations, Female, Gallbladder Diseases diagnosis, Humans, Male, Middle Aged, Monoterpenes adverse effects, Multivariate Analysis, Pain Measurement, Pain, Postoperative diagnosis, Pain, Postoperative etiology, Proportional Hazards Models, Prospective Studies, Republic of Korea, Risk Factors, Single-Blind Method, Surveys and Questionnaires, Time Factors, Treatment Outcome, Abdominal Pain prevention & control, Analgesics administration & dosage, Cholecystectomy, Laparoscopic adverse effects, Gallbladder Diseases surgery, Monoterpenes administration & dosage, Pain, Postoperative prevention & control
- Abstract
Background: Postcholecystectomy pain (PCP) is characterized by abdominal pain after cholecystectomy. However, prevention of PCP is not well known yet. The purpose of this study was to determine whether Rowachol might be useful in preventing PCP., Methods: Between May 2013 and January 2014, a total of 138 patients with gallbladder disease who were scheduled to undergo laparoscopic cholecystectomy were randomly assigned to orally receive 100 mg Rowachol or placebo three times daily for 3 months after surgery. Abdominal pain was assessed using the European Organization for Research and Treatment of Cancer QLQ-C30 questionnaire., Results: Incidence of PCP in the placebo group (n = 9, 14.3%) was higher than that in the Rowachol group (n = 3, 4.7%) with statistically marginal significance (P = 0.08). Risk factor analysis implicated PCP with increased difficulty in performing LC, more frequent pathology with acute cholecystitis, and absence of postoperative Rowachol treatment. Multivariate analysis revealed that greater difficulty of laparoscopic cholecystectomy (HR = 5.78, 95% CI 1.36-24.40, P < 0.05), and absence of postoperative Rowachol treatment (HR = 2.54, 95% CI 1.10-10.39, P < 0.05) were independent risk factors for development of PCP., Conclusion: Rowachol might be beneficial for prevention of PCP after laparoscopic cholecystectomy., (Copyright © 2016 International Hepato-Pancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF